No Help From Dual RAAS Blockade in PKD

November 17, 2014 6:39 PM

12 0

PHILADELPHIA -- Two large trials have shown that combination therapy with an ACE inhibitor plus an angiotensin receptor blocker (ARB) doesn't offer any renal benefits for patients with autosomal dominant polycystic kidney disease (ADPKD), researchers reported here.

In the HALT-PKD trials, the combination didn't reduce kidney volume among patients in early stages of the disease, and it didn't diminish a composite endpoint of death, end-stage renal disease (ESRD), or a 50% reduction in baseline eGFR among those in the later stages, two groups reported here at Ki...

Read more

To category page